Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50929
Name mucosal melanoma
Definition A melanoma that has_material_basis_in melanocytes located_in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer melanoma mucosal melanoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT C443S Imatinib mucosal melanoma sensitive detail...
BRAF V600L Dabrafenib + Trametinib mucosal melanoma predicted - sensitive detail...
KIT N822K Avapritinib mucosal melanoma predicted - sensitive detail...
KIT exon17 Avapritinib mucosal melanoma predicted - sensitive detail...
EML4 - ALK Crizotinib mucosal melanoma sensitive detail...
EML4 - ALK Ceritinib mucosal melanoma sensitive detail...
EML4 - ALK Entrectinib mucosal melanoma sensitive detail...
EML4 - ALK ASP3026 mucosal melanoma sensitive detail...
EML4 - ALK Alectinib mucosal melanoma sensitive detail...
NRAS Q61H Trametinib mucosal melanoma sensitive detail...
NRAS Q61L Belvarafenib mucosal melanoma predicted - sensitive detail...
BRAF D594G Belvarafenib mucosal melanoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02645149 Phase II Trametinib Pazopanib Ceritinib Ribociclib + Trametinib Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) Recruiting AUS 0
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Terminated USA 0
NCT02818023 Phase I Cobimetinib + Pembrolizumab + Vemurafenib Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Terminated USA 0
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Unknown status CAN 0
NCT02978443 Phase II Ipilimumab + Nivolumab A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Terminated USA 0
NCT03220009 Phase II Ipilimumab + Nivolumab Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn USA 0
NCT03235245 Phase II Binimetinib + Encorafenib Ipilimumab + Nivolumab Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) Active, not recruiting NLD | ITA | GBR | FRA | ESP | DEU 3
NCT03241186 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Active, not recruiting USA 0
NCT03313206 Phase II Pembrolizumab Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ) Recruiting FRA 0
NCT03340129 Phase II Ipilimumab + Nivolumab Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) Recruiting AUS 1
NCT03817125 Phase I Nivolumab + SER-401 Vancomycin Nivolumab Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) Completed USA 0
NCT03875079 Phase I Pembrolizumab + RO6874281 A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma Completed USA | FRA | ESP | CAN | BEL | AUS 1
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Recruiting USA 0
NCT04042506 Phase II Nivolumab SBRT as a Vaccination for Metastatic Melanoma Withdrawn USA 0
NCT04139902 Phase II Cobolimab + Dostarlimab-gxly Dostarlimab-gxly PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) Recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04318717 Phase Ib/II Pembrolizumab Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma Recruiting USA 0
NCT04493203 Phase II Axitinib + Nivolumab Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Active, not recruiting USA 0
NCT04551352 Phase I RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Completed USA | ESP | CAN | BEL | AUS 1
NCT04570332 Phase II BO-112 + Pembrolizumab BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203) Active, not recruiting FRA | ESP 0
NCT04577807 Phase II PVSRIPO + unspecified PD-1 antibody PVSRIPO PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma Active, not recruiting USA 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Recruiting USA | ESP 0
NCT04830124 Phase II ALKS 4230 Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6) Recruiting USA | ITA | GBR | ESP | CAN | AUS 2
NCT04987996 Phase II Pembrolizumab Belapectin + Pembrolizumab GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients Withdrawn USA 0
NCT05061134 Phase II Ceralasertib + Durvalumab Ceralasertib A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05098210 Phase I NeoVax + Nivolumab + Poly ICLC Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer Recruiting USA 0
NCT05111574 Phase II Nivolumab Cabozantinib + Nivolumab Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Recruiting USA | CAN 0
NCT05384496 Phase II Axitinib + Ipilimumab + Nivolumab Axitinib + Nivolumab Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Recruiting USA 0
NCT05415072 Phase Ib/II DYP688 A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Recruiting USA | NLD | FRA | ESP | DEU | AUS 1
NCT05428007 Phase II Ipilimumab + Nivolumab and relatlimab-rmbw + Sarilumab Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Recruiting USA 0
NCT05482074 Phase II Olaparib Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Withdrawn 0
NCT05545969 Phase II Lenvatinib + Pembrolizumab Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM) Not yet recruiting AUS 0
NCT05628883 Phase I Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Recruiting USA 0
NCT05913388 Phase II Pembrolizumab GB1211 + Pembrolizumab GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT06319196 Phase II Nivolumab Nivolumab and relatlimab-rmbw Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe) Recruiting CAN 0